Arbutus Biopharma (ABUS) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Arbutus Biopharma (ABUS): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why ABUS has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with ABUS. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
These figures are approximate and tied to the Jul 2026 asOf date; verify live trial status, settlement terms and receipts, and cash figures against Arbutus's latest quarterly filings before acting. Traditional valuation multiples do not apply cleanly to a pre-revenue biotech: the stock is driven by clinical data, regulatory milestones, and, unusually here, the litigation settlement cash, so earnings snapshots are less meaningful than pipeline progress and balance-sheet strength.
What could move ABUS from here
In short: the drivers cited most often are Imdusiran functional-cure program, Moderna settlement and cash, Combination and pipeline breadth. The risk cited most often against it is arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ABUS is it a buy page. This page deliberately stops at the numbers.
Investing in Arbutus Biopharma with AI
Connect the broker you already use and ask Walnut's AI how ABUS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Arbutus Biopharma (ABUS)?
+
There is no meaningful consensus price target for ABUS, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does ABUS have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move ABUS?
+
The drivers and the risks are laid out on this page and in more depth on the ABUS "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a July 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.